Table 1.
Demographic and clinical characteristics of our population sample.
| N° | 158 |
|---|---|
| Female (%) | 54.4 |
| Age (years)* | 55.5 (47.1–63.6) |
| Age men* | 56.2 (47.2–63.6) |
| Age women* | 55.4 (47.1–63.7) |
| Disease duration (years)* | 10.6 (9.3–11.9) |
| Subjects without caregivers (%) | 38.6 |
| Education (%) | |
| Elementary school | 15 |
| Secondary school | 45 |
| High school | 31 |
| Degree | 9 |
| Family members* | 3 (2–4) |
| Smokers (%) | 24.7 |
| Alcohol consumption (%) | 5.7 |
| CASPAR; Criteria | 5 (4–6) |
| DAPSA§ | 19.02 (9–33.1) |
| Facit Fatigue* | 35 (20–43) |
| PHQ-9¥ | 7 (4–13) |
| HAQ¶ | 1 (0.25–1.75) |
| PSAID$ | 4 (2–6) |
| CRP (mg/l)* | 1.47 (0.34–3.05) |
| 66 Swollen Joint Count* | 2 (0–6) |
| 68 Tender Joint Count* | 4 (0–13) |
| PASI: | 1 (0–2) |
| csDMARDs|| | 41.6 |
| Methotrexate (%) | 78 |
| Leflunomide (%) | 10 |
| Sulfasalazine (%) | 7 |
| Cyclosporine (%) | 3 |
| Hydroxychloroquine (%) | 2 |
| bDMARDs** | 81.3 |
| Anti TNF-Alpha (%) | 69 |
| Anti IL 17 (%) | 13 |
| Small Molecules (%) | 13 |
| Anti- IL 12–23 (%) | 4 |
| Anti IL-23 (%) | 1 |
| Combination of csDMARDs and bDMARDs | 74.5 |
Population characteristics. *Data are reported as median (interquartile range). Data are presented as n (%). CASPAR (ClASsification criteria for Psoriatic Arthritis); §DAPSA (Disease Activity in Psoriatic Arthritis); ¥PHQ-9 (Patient Health Questionnaire-9); ¶HAQ (Health Assessment Questionnaire); $PSAID (Psoriatic Arthritis Impact of Disease); PASI (Psoriasis Area Severity Index); ||csDMARD(Synthetic disease-modifying anti-rheumatic drugs); **bDMARD (Biologic Disease-modifying Anti-rheumatic Drug).